Tag Archives: More

Glaxo's ViiV touts more two-drug HIV success with monthly injectable win

GlaxoSmithKline’s ViiV Healthcare has already shown that a two-drug HIV regimen can hang with its three-drug competitors. But now it has data showing it can do the same with administration just once per month. Thursday, ViiV rolled out results from two studies showing an injection pairing its own cabotegravir with Johnson & Johnson’s rilpivirine (Edurant), given once every four… Read More »